• D&D Pharmatech cut the conversion price on its second-series convertible bonds to KRW 54,416 from KRW 77,736.
• The adjustment takes effect Oct. 30, 2026, reflecting a decline in the share price.
• Shares issuable upon conversion increase to 4,162,353 from 2,913,691.
• Outstanding convertible bonds total KRW 226.5 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. D&D Pharmatech Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030901174), on October 30, 2026, and is solely responsible for the information contained therein.